Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 11, 2010, Pages 1627-1631

  Guo, Qingqu ^a   Kang, Muxing ^a   Zhang, Bo ^a   Chen, Ying ^a   Dong, Xin ^a   Wu, Yulian ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

CA19 9; CEA; Diabetes; Pancreatic cancer

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GLUCOSE; ALANINE AMINOTRANSFERASE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SCREENING; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; EARLY DIAGNOSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREAS SURGERY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; ADENOCARCINOMA; BLOOD; COMPLICATION; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; REFERENCE VALUE;

ADENOCARCINOMA; AGED; ALANINE TRANSAMINASE; BILIRUBIN; BLOOD GLUCOSE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIABETES MELLITUS; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES;

EID: 77957550141     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0820-0     Document Type: Article

References (29)

1. G Banfi A Ardemagni S Bravi, et al. 1996 Are diabetic metabolic compensation and CA19.9 really correlated? Int J Biol Markers 11 207 210 1:STN:280:DyaK2s7mvF2jsw%3D%3D 9017444
2. E Cersosimo PW Pisters G Pesola, et al. 1991 Insulin secretion and action in patients with pancreatic cancer Cancer 67 486 493 1:STN:280: DyaK3M%2FptFOrug%3D%3D 10.1002/1097-0142(19910115)67:2<486::AID- CNCR2820670228>3.0.CO;2-1 1985741
3. MC Chang YT Chang TC Su, et al. 2007 Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis Pancreas 35 16 21 1:CAS:528:DC%2BD2sXotlWnsbY%3D 10.1097/MPA.0b013e3180547709 17575540 (Pubitemid 46956196)
4. ST Chari GG Klee LJ Miller, et al. 2001 Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer Gastroenterology 121 640 645 1:CAS:528:DC%2BD3MXntVKnsbg%3D 10.1053/gast.2001.27210 11522748
5. ST Chari CL Leibson KG Rabe, et al. 2005 Probability of pancreatic cancer following diabetes: a population-based study Gastroenterology 129 504 511 16083707
6. ST Chari CL Leibson KG Rabe, et al. 2008 Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer Gastroenterology 134 95 101 1:CAS:528:DC%2BD1cXhtlehsbc%3D 10.1053/j.gastro. 2007.10.040 18061176 (Pubitemid 350309328)
7. CG Clark PE Mitchell 1961 Diabetes mellitus and primary carcinoma of the pancreas Br Med J 2 1259 1262 1:STN:280:DyaF38%2FitV2ltA%3D%3D 10.1136/bmj.2.5262.1259 13879669
8. JP Duffy G Eibl HA Reber, et al. 2003 Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer Mol Cancer 2 12 10.1186/1476-4598-2-12 12605718 (Pubitemid 38751485)
9. J Everhart D Wright 1995 Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis J Am Med Assoc 273 1605 1609 1:STN:280:DyaK2M3msVGhtg%3D%3D 10.1001/jama.273.20.1605
10. LC Fry K Monkemuller P Malfertheiner 2008 Molecular markers of pancreatic cancer: development and clinical relevance Langenbecks Arch Surg 393 883 890 10.1007/s00423-007-0276-0 18266003
11. L Gullo R Pezzilli AM Morselli-Labate 1994 Diabetes and the risk of pancreatic cancer N Engl J Med 331 81 84 1:STN:280:DyaK2c3mvVGhug%3D%3D 10.1056/NEJM199407143310203 8208269 (Pubitemid 24202222)
12. Q Guo B Zhang X Dong, et al. 2009 Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor Pancreas 38 e75 e79 1:CAS:528:DC%2BD1MXjsVyqtrY%3D 10.1097/MPA.0b013e3181987d86 19276866
13. A Jemal R Siegel E Ward, et al. 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 17237035
14. CM Kang JY Kim GH Choi, et al. 2007 The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer J Surg Res 140 31 35 1:CAS:528:DC%2BD2sXkvFOqsrs%3D 10.1016/j.jss.2006.10.007 17418869 (Pubitemid 46669540)
15. TT Kuang D Jin D Wang, et al. 2009 Clinical epidemiological analysis of the relationship between pancreatic cancer and diabetes mellitus: data from a single institution in China J Digest Dis 10 26 29 10.1111/j.1751-2980.2008. 00359.x
16. N Nakamura O Aoji T Yoshikawa, et al. 1986 Elevated serum CA19-9 levels in poorly controlled diabetic patients Jpn J Med 25 278 280 1:STN:280: DyaL2s%2FjslGksA%3D%3D 3464790
17. A Noy JP Bilezikian 1994 Clinical review 63: diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy J Clin Endocrinol Metab 79 1223 1231 1:CAS:528:DyaK2MXit1eksrs%3D 10.1210/jc.79.5.1223 7962312 (Pubitemid 24369827)
18. Y Ogawa M Tanaka K Inoue, et al. 2002 A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus Cancer 94 2344 2349 10.1002/cncr.10493 12015758 (Pubitemid 34457114)
19. R Pannala JB Leirness WR Bamlet, et al. 2008 Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus Gastroenterology 134 981 987 1:CAS:528:DC%2BD1cXls1Gmurk%3D 10.1053/j.gastro.2008.01.039 18395079 (Pubitemid 351451984)
20. R Pannala A Basu GM Petersen, et al. 2009 New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer Lancet Oncol 10 88 95 10.1016/S1470-2045(08)70337-1 19111249
21. J Permert J Larsson I Ihse, et al. 1991 Diagnosis of pancreatic cancer: alteration of glucose metabolism Int J Pancreatol 9 113 117 1:STN:280: DyaK38%2FnvVKntw%3D%3D 1744436
22. J Permert I Ihse L Jorfeldt, et al. 1993 Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer Br J Surg 80 1047 1050 1:STN:280:DyaK2c%2FgsFGrsw%3D%3D 10.1002/bjs.1800800841 8402064 (Pubitemid 23261595)
23. J Permert I Ihse L Jorfeldt, et al. 1993 Pancreatic cancer is associated with impaired glucose metabolism Eur J Surg 159 101 107 1:STN:280: DyaK3s3msVGjtg%3D%3D 8098623 (Pubitemid 23112386)
24. JM Petit G Vaillant NO Olsson, et al. 1994 Elevated serum CA19-9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group Gastroenterol Clin Biol 18 17 20 1:STN:280:DyaK2c3ksVyrtA%3D%3D 8187985
25. F Rivera S Lopez-Tarruella ME Vega-Villegas, et al. 2009 Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy Cancer Treat Rev 35 335 339 1:CAS:528:DC%2BD1MXmtlOqtrw%3D 10.1016/j.ctrv.2008.11.007 19131170
26. N Shimojo K Naka C Nakajima, et al. 1990 The effect of non-insulin-dependent diabetes on serum concentrations of tumor-associated carbohydrate antigens of CA19-9, CA-50, and sialyl SSEA-1 in association with the Lewis blood phenotype Clin Chim Acta 190 283 289 1:STN:280: DyaK3M%2FntVyisQ%3D%3D 10.1016/0009-8981(90)90182-R 1979260 (Pubitemid 20298569)
27. Sobin LH, Wittekind C (eds) (2002) UICC: TNM classification of malignant tumours. Wiley, London
28. O Uygur-Bayramicli R Dabak E Orbay, et al. 2007 Type 2 diabetes mellitus and CA 19-9 levels World J Gastroenterol 13 5357 5359 1:CAS:528: DC%2BD2sXht1yitLjN 17879406
29. F Wang S Gupta EA Holly 2006 Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California Cancer Epidemiol Biomarkers Prev 15 1458 1463 10.1158/1055-9965.EPI-06-0188 16896032 (Pubitemid 44299315)